Stay updated with breaking news from Nrh A. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The expanded approval makes enzalutamide the first and only approved androgen receptor signaling inhibitor in the nonmetastatic castration-sensitive prostate cancer setting.
In a subset of patients with high-risk prostate cancer, the combination of abiraterone acetate plus prednisone (AAP) and apalutamide may improve outcomes when added to salvage radiation therapy.
Although the disease afflicts at least 1 out of every 10 women, endometriosis remains a conundrum for patients and their physicians.
It appears that bone health deserves attention when adolescents are placed on gender-affirming hormone therapy.
In premenopausal women with early breast cancer, use of a gonadotropin-releasing hormone agonist during chemotherapy did not increase the risk of cancer recurrence for up to 12 years, according to the PROMISE-GIM6 trial.